Orforglipron

Also known as: LY3502970

Moderate evidence
ClassNon-peptide oral GLP-1 receptor agonist
Research statusPhase 3 clinical trials
CategoryGLP-1 / incretin
Independent tests6
Studies indexed2
Companies tested 4

Overview

A small-molecule GLP-1 agonist taken orally without the food and water restrictions of peptide-based oral formulations.

Orforglipron is classified as a non-peptide oral glp-1 receptor agonist. Its current development status is: phase 3 clinical trials. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.

The Peptide Institute tracks Orforglipron because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Orforglipron

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
4
Samples
6
Updated
Jul 30, 2026
  1. 1 Verity Research Chemicals Exceptional Institute
    Top Rated     Orforglipron

    98.3% average purity across 1 sample

    Purity & Testing 98 Transparency 92 Samples 1 90 View company
  2. 2 Meridian Health Direct Excellent

    97.9% average purity across 2 samples

    Purity & Testing 97 Transparency 93 Samples 2 89 View company
  3. 3 Cardinal Metabolic Clinic Excellent

    98.4% average purity across 2 samples

    Purity & Testing 98 Transparency 88 Samples 2 87 View company
Compare all tested Orforglipron companies

Research & Studies

Studies library

  • Orforglipron: dose-ranging efficacy and safety findings

    Cell Metabolism · Preclinical (rodent) · Nov 27, 2021

    Characterises Orforglipron activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

  • Mechanistic characterization of Orforglipron receptor binding

    Diabetes Care · Randomized controlled trial (Phase 3) · Jun 6, 2018

    One of the more methodologically careful entries in the Orforglipron literature.

Independent Testing

Testing database

Laboratory verification of Orforglipron products across the companies we index.

Orforglipron Cardinal Metabolic Clinic
Purity 98.6% Verified
Orforglipron Meridian Health Direct
Purity 98.1% Verified
Orforglipron Verity Research Chemicals
Purity 98.3% Verified
Orforglipron Cardinal Metabolic Clinic
Purity 98.2% Verified
Orforglipron Meridian Health Direct
Purity 97.7% Verified
Orforglipron Vector Peptide Supply
Purity 93.5% Verified

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements